GAO Negative On Third Class Of Drugs For USA

10 September 1995

In the USA, medicines are available on prescription only through pharmacies or without prescription in any outlet. However, at the request of Representative Dingell, the General Accounting Office has conducted a study of the situation, from which it has concluded that the "evidence for creating an additional class of drugs in the USA that would not be for sale outside pharmacies but would be available without a physician's prescription" does not support the introduction of a third class of drugs at this time.

The GAO reviewed the situation in 10 countries which have a pharmacy-only drug category (Australia, Canada, Denmark, France, Germany, Italy, the Netherlands, Sweden, Switzerland and the UK) and also considered the European Union's harmonized distribution system. As far as the latter was concerned, the GAO noted that the EU has decided it will not impose a particular drug distribution system on member countries because there is insufficient evidence to recommend one system over another. Indeed, the GAO report stated, EU officials think the three-class system is ineffective in minimizing health concerns or promoting trade.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight